
Heat Flow (Normalized) (W/g)
Temperature T (°C)
Enthalpy (normalized): 44.135 J/g
Onset x: 51.278 °C
Enthalpy (normalized): 61.741 J/g
Onset x: 138.840 °C

FIG. 1


Counts
3.207°
8.224°
9.864°
12.681°
16.355°
16.419°
16.917°
17.570°
19.864°
20.557°
21.196°
22.080°
22.911°
23.403°
23.909°
24.219°
24.908°
25.408°
27.090°
28.164°
29.190°
29.876°
30.930°
31.516°
32.303°
34.759°
35.706°

FIG. 2


Weight (%)
100
96
88
84
82
80
Temperature (°C)
0
50
100
150
200
250
1.476% wt loss to 100 deg C (water)
(0.1162mg)
weight loss due to thermal decomposition

FIG. 3


Enthalpy (normalized): 63.264 J/g
Onset x: 27.677 °C
Enthalpy (normalized): 68.454 J/g
Onset x: 153.651 °C
Heat Flow (Normalized) (W/g)
Temperature (°C)
Exo Up
0.75
0.50
0.25
0.00
-0.25
-0.50
-0.75
-1.00
-1.25
-1.50
-1.75
0
50
100
150
200
250
300

FIG. 4


709 polymorph
Counts
7.811
8.663
8.042
10.763
12.207
13.444
13.738
15.991
16.420
17.564
17.304
19.540
21.857
21.898
22.899
23.246
23.757
24.246
24.885
26.199
28.092
28.805
29.192
29.896
30.820
31.568
38.738

FIG. 5


2.120% wt loss to 100 deg C (water)
(0.2661mg)
weight loss due to thermal decomposition
Weight (%)
100
98
96
94
92
90
0
50
100
150
200
25
Temperature (°C)

FIG. 6


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
Percent of baseline bodyweight (%)
110
105
100
95
90
85
1 3 5 7 9 11 13 15 17 19 21 23 25
(Days)

FIG. 7


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
AUC of Bodyweight Percentage
3000
2000
1000
0
experimental groups

FIG. 8


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
EAE score
2.5
2.0
1.5
1.0
0.5
0.0
1 3 5 7 9 11 13 15 17 19 21 23 25
(Days)

FIG. 9


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
AUC of EAE Clinical Scores
0
5
10
15
20
experimental groups

FIG. 10


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
Cumulative disease score
1.5
1.0
0.5
0.0
experimental groups

FIG. 11


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
EAE score
2.5
2.0
1.5
1.0
0.5
0.0
1 3 5 7 9 11 13 15 17 19 21 23 25
(Days)

FIG. 12


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
AUC of EAE Clinical Scores
0
5
10
15
20
25
experimental groups

FIG. 13


Vehicle
Compound 1 therapeutic
% of symptoms free animals
100
75
50
25
0
0
5
10
15
20
25
(Days)
Vehicle
Compound 1 prophylactic
% of symptoms free animals
100
75
50
25
0
0
5
10
15
20
25
(Days)

FIG. 14


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
Spleen weight (gr)
0.3
0.2
0.1
0.0

FIG. 15


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
IFN-γ pg/mL
60
40
20
0
experimental groups

FIG. 16


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
IL-6 pg/mL
0
20
40
60
experimental groups

FIG. 17


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
IL-10 pg/mL
60
40
20
0
experimental groups

FIG. 18


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
IL-17a pg/mL
0
10
20
30
40
50
experimental groups

FIG. 19


Vehicle
Compound 1 prophylactic
Compound 1 therapeutic
Dexamethasone
TNF-α pg/mL
80
60
40
20
0
experimental groups

FIG. 20


Body Weight (+/- SD)
Group 01: Naive
Group 02: Vehicle BID
Group 03: Compound 1 75mg/kg BID
Group 04: Compound 1 25mg/kg BID
Group 05: Compound 1 100mg/kg QD PM
+ Vehicle QD AM
Weight (g)
24
22
20
18
16
14
0
4
8
12
16
20
24
28
Study Days

FIG. 21


% Change in Body Weight from initial
(+/- SD)
Group 01: Naive
Group 02: Vehicle BID
Group 03: Compound 1 75mg/kg BID
Group 04: Compound 1 25mg/kg BID
Group 05: Compound 1 100mg/kg QD PM
+ Vehicle QD AM
% Body Weight Change
20
10
0
-10
-20
0
4
8
12
16
20
24
28
Study Days

FIG. 22


BC 1
Mouse is emaciated.
- Skeletal structure extremely prominent; little or no flesh cover.
- Vertebrae distinctly segmented.
BC 2
Mouse is underconditioned.
- Segmentation of vertebral column evident.
- Dorsal pelvic bones are readily palpable.
BC 3
Mouse is well-conditioned.
- Vertebrae and dorsal pelvis not prominent; palpable with slight pressure.
BC 4
Mouse is overconditioned.
- Spine is a continuous column.
- Vertebrae palpable only with firm pressure.
BC 5
Mouse is obese.
- Mouse is smooth and bulky.
- Bone structure disappears under flesh and subcutaneous fat.
A "+" or a "-" can be added to the body condition score if additional increments are necessary (i.e. ...2+, 2, 2-...)

FIG. 23


Body Condition Score (+/- SD)
Mean Score
3.5
3.0
2.5
2.0
1.5
0
4
8
12
16
20
24
28
Study Days
Group 01: Naive
Group 02: Vehicle BID
Group 03: Compound 1 75mg/kg BID
Group 04: Compound 1 25mg/kg BID
Group 05: Compound 1 100mg/kg QD PM
+ Vehicle QD AM

FIG. 24


Disease Score (+/- SD)
Mean Score
Study Days
Group 01: Naive
Group 02: Vehicle BID
Group 03: Compound 1 75mg/kg BID
Group 04: Compound 1 25mg/kg BID
Group 05: Compound 1 100mg/kg QD PM
+ Vehicle QD AM

FIG. 25


Incidence data for TRE-515
Percent disease-free mice
100
50
0
0
7
14
21
28
Days
Naive
Vehicle BID (12hr)
Compound 1 75mg/kg BID (12hr)
Compound 1 25mg/kg BID (12hr)
Compound 1 100mg/kg QD PM
+ Vehicle QD AM

FIG. 26


Spleen weight +/- SD
Weight/g
0.3
0.2
0.1
0.0
Group 01: Naïve
Group 02: Vehicle BID
Group 03: Compound 1 75mg/kg BID
Group 04: Compound 1 25mg/kg BID
Group 05: Compound 1 100mg/kg QD PM+ Veh. QD AM

FIG. 27